Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:CMPXNASDAQ:ETNBNASDAQ:MESO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$65.59+0.5%$63.90$52.50▼$77.00$1.42B0.57312,580 shs33,299 shsCMPXCompass Therapeutics$2.76-0.9%$2.22$0.82▼$4.08$380.96M1.48968,205 shs82,085 shsETNB89BIO$10.10-0.6%$9.26$4.16▼$11.84$1.47B1.282.23 million shs154,986 shsMESOMesoblast$10.48-1.9%$11.30$5.78▼$22.00$1.34B2.39276,621 shs67,882 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals0.00%-0.32%+5.38%-2.54%+6.27%CMPXCompass Therapeutics0.00%+8.40%+11.00%+76.75%+246.88%ETNB89BIO0.00%+2.84%-1.07%+84.70%+34.84%MESOMesoblast0.00%-1.19%-8.48%+3.75%+39.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.83 of 5 stars2.51.00.03.32.63.31.3CMPXCompass Therapeutics3.377 of 5 stars3.62.00.00.03.35.00.0ETNB89BIO1.5624 of 5 stars3.51.00.00.01.10.80.6MESOMesoblast2.3364 of 5 stars3.51.00.00.03.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$80.1322.17% UpsideCMPXCompass Therapeutics 3.10Buy$12.67359.77% UpsideETNB89BIO 3.00Buy$26.43161.80% UpsideMESOMesoblast 3.00Buy$18.0071.76% UpsideCurrent Analyst Ratings BreakdownLatest CMPX, ETNB, ANIP, and MESO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025CMPXCompass TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform$9.006/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/10/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/9/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.004/30/2025ETNB89BIOCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/22/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.31$7.64 per share8.59$19.11 per share3.43CMPXCompass Therapeutics$850K448.19N/AN/A$0.91 per share3.03ETNB89BION/AN/AN/AN/A$3.34 per shareN/AMESOMesoblast$5.90M226.97N/AN/A$4.21 per share2.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.58N/A-3.12%21.35%7.52%8/5/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.41N/AN/AN/AN/A-42.47%-38.31%8/11/2025 (Estimated)ETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)MESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)Latest CMPX, ETNB, ANIP, and MESO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025ETNB89BIO-$0.49N/AN/AN/AN/AN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.462.661.98CMPXCompass TherapeuticsN/A8.338.33ETNB89BIO0.0618.0318.03MESOMesoblast0.220.960.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%CMPXCompass Therapeutics68.43%ETNB89BION/AMESOMesoblast1.43%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%CMPXCompass Therapeutics29.80%ETNB89BIO2.80%MESOMesoblast18.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million18.91 millionOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableETNB89BIO40145.98 million141.90 millionOptionableMESOMesoblast80127.78 million103.76 millionOptionableCMPX, ETNB, ANIP, and MESO HeadlinesRecent News About These CompaniesMesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?July 2, 2025 | marketbeat.comMesoblast Shares Surge on FDA AlignmentJuly 1, 2025 | sharecafe.com.auSMesoblast, FDA agree on marketing application for cell therapyJuly 1, 2025 | msn.comMesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?July 1, 2025 | marketbeat.comMesoblast Targets Accelerated FDA Approval For Heart Failure Drug RevascorJuly 1, 2025 | benzinga.comFinancial Survey: Mesoblast (NASDAQ:MESO) vs. Rallybio (NASDAQ:RLYB)July 1, 2025 | americanbankingnews.comMesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart FailureJune 30, 2025 | globenewswire.comMesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for RyoncilJune 29, 2025 | msn.comMesoblast (NASDAQ:MESO) Shares Down 4.2% - Here's What HappenedJune 23, 2025 | marketbeat.comMesoblast Limited (MSB.AX)June 22, 2025 | finance.yahoo.comProsperity Wealth Management Inc. Has $608,000 Stock Position in Mesoblast Limited (NASDAQ:MESO)June 18, 2025 | marketbeat.comMesoblast Limited (NASDAQ:MESO) Shares Purchased by GAMMA Investing LLCJune 16, 2025 | marketbeat.comMesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’June 12, 2025 | msn.comMesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHDJune 11, 2025 | globenewswire.comMesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?June 11, 2025 | marketbeat.comMesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug ApprovalJune 10, 2025 | finance.yahoo.comMesoblast (NASDAQ:MESO) Trading Up 6.2% - Here's What HappenedJune 10, 2025 | marketbeat.comCantor Fitzgerald Predicts Mesoblast FY2026 EarningsJune 10, 2025 | marketbeat.comWhich S&P 500 Move Matters?May 27, 2025 | msn.comHotCopper Highlights Week 20: Mesoblast FDA miss; Larvotto posts tungsten, Melbana & MoreMay 16, 2025 | msn.comMesoblast Limited: FDA Provides Seven Years of Orphan-Drug Exclusive Approval for RyoncilMay 15, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPX, ETNB, ANIP, and MESO Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$65.58 +0.31 (+0.47%) As of 11:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Compass Therapeutics NASDAQ:CMPX$2.76 -0.03 (-0.90%) As of 11:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.89BIO NASDAQ:ETNB$10.10 -0.07 (-0.64%) As of 11:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Mesoblast NASDAQ:MESO$10.48 -0.20 (-1.87%) As of 11:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story CAVA Group: Why the Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
